The phase III VIALE-A clinical trial evaluating newly-diagnosed AML patients who had not yet been treated and were unable to tolerate traditional intensive chemotherapy, found that venetoclax in combination with azacitidine extended overall survival compared to azacitidine plus placebo.
Elizabeth Comen originally set out to write a book about the wellness industry, but ended up writing a different book altogether.
